Sun Pharmaceutical Industries Limited — PPTs, 07-07-2026: Investor Presentation

Here's a concise, retail-friendly summary of Sun Pharma's investor presentation:

**1. Business Performance:**

Sun Pharma posted strong FY26 sales of Rs 58,220.1 Cr, up 11.9% YoY. India Formulations (33% of sales) remained India's largest pharma business. US Formulations contributed 29%, with Innovative Medicines (22% of total sales) growing to USD 1.42 billion globally.

**2. Growth Drivers or Strategy:**

Strategic focus areas include boosting innovative and complex product contributions, optimizing costs, and leveraging acquisitions for portfolio and market expansion. Sustainability practices are also a core growth strategy.

**3. Recent Developments:**

FY26 saw Leqselvi and Unloxcyt launched in the US. The company also announced the 2026 acquisition of Organon & Co. to boost global scale, adding Women's Health and biosimilar segments.

**4. Key Financial Metrics:**

For FY26, EBITDA surged 16.1% to Rs 17,731.4 Cr (30.3% margin). Adjusted Net Profit grew 3.5% to Rs 12,401.5 Cr. R&D investments reached Rs 3,554 Cr (6.1% of sales); Adjusted EPS hit Rs 51.7.

**5. Management Commentary / Outlook:**

Management aims to expand the innovative medicines pipeline, sustain market leadership in India, and drive profitable growth across Emerging Markets. Regulatory compliance and improving return ratios remain key priorities.